Several treatments have been approved by the US Food and Drug Administration (FDA) for the treatment of hematopoietic subsyndrome of ARS (H-ARS), including two preparations of granulocyte colony-stimulating factor (G-CSF), one preparation of granulocyte-macrophage colony-stimulating factor (GM-CSF), and one preparation of romiplostim, a thrombopoietin receptor agonist [1, 3]. Here, CSF2 is linked to Axenfeld-Rieger syndrome.